T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
Sight Sciences
SGHT
$267M
| $96K | ﹤0.01% |
25,283
| – | – |
|
3002
eHealth
EHTH
$42.5M
| $95K | ﹤0.01% |
73,336
+15,600
| +27% | +$36.2K |
|
3003
Nuvectis Pharma
NVCT
$609M
| $94K | ﹤0.01% |
+12,048
| New | +$103K |
|
3004
Fate Therapeutics
FATE
$281M
| $92K | ﹤0.01% |
76,633
+22,163
| +41% | +$27K |
|
3005
New Fortress Energy
NFE
$101M
| $92K | ﹤0.01% |
154,547
+36,255
| +31% | +$42.4K |
|
3006
NN Inc
NNBR
$272M
| $92K | ﹤0.01% |
63,163
| – | – |
|
3007
SEACOR Marine Holdings
SMHI
$216M
| $92K | ﹤0.01% |
12,764
| – | – |
|
3008
Priority Technology Holdings
PRTH
$518M
| $91K | ﹤0.01% |
19,248
+6,554
| +52% | +$35.9K |
|
3009
Heron Therapeutics
HRTX
$86.3M
| $90K | ﹤0.01% |
111,504
+34,866
| +45% | +$40.4K |
|
|
FIRY
3010
Firy Inc
FIRY
$127M
| $89K | ﹤0.01% |
34,215
| – | – |
|
3011
CuriosityStream
CURI
$139M
| $88K | ﹤0.01% |
29,683
+13,607
| +85% | +$45.9K |
|
|
KLC
3012
KinderCare Learning Companies
KLC
$584M
| $88K | ﹤0.01% |
39,733
+6,130
| +18% | +$23.1K |
|
3013
CareCloud
CCLD
$94.3M
| $87K | ﹤0.01% |
23,700
| – | – |
|
|
LPRO
3014
Open Lending Corp
LPRO
$373M
| $87K | ﹤0.01% |
69,287
+15,405
| +29% | +$24.4K |
|
3015
Inhibikase Therapeutics
IKT
$366M
| $86K | ﹤0.01% |
50,874
+20,268
| +66% | +$36K |
|
3016
Lucid Diagnostics
LUCD
$173M
| $86K | ﹤0.01% |
74,377
+39,241
| +112% | +$49.9K |
|
3017
TriSalus Life Sciences
TLSI
$259M
| $86K | ﹤0.01% |
21,294
+6,480
| +44% | +$31.7K |
|
|
AOMR
3018
Angel Oak Mortgage REIT
AOMR
$219M
| $85K | ﹤0.01% |
+10,222
| New | +$88.9K |
|
3019
Cardiff Oncology
CRDF
$64.3M
| $85K | ﹤0.01% |
52,316
+20,986
| +67% | +$43.1K |
|
3020
Century Casinos
CNTY
$32.9M
| $84K | ﹤0.01% |
59,831
| – | – |
|
3021
Crexendo
CXDO
$215M
| $84K | ﹤0.01% |
+13,545
| New | +$88.9K |
|
|
AGEN
3022
Agenus
AGEN
$249M
| $82K | ﹤0.01% |
24,500
| – | – |
|
3023
Children's Place
PLCE
$53.6M
| $80K | ﹤0.01% |
23,539
| – | – |
|
3024
Knightscope
KSCP
$25M
| $79K | ﹤0.01% |
18,900
| – | – |
|
3025
LifeVantage
LFVN
$82.4M
| $79K | ﹤0.01% |
18,234
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.